In the analyses of antitumor immunity, the combination therapy of butyrate and OBP-702 significantly recruited CD8 + T cells (Fig. 4E) and increased MHC-I expression in the tumor tissues harvested 14 days after the first OBP-702 injection, compared with each monotherapy (Fig. S5C). The gene discussed is CD8A; the disease is neoplasm.